Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05510427
Title Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

cholangiocarcinoma

Therapies

Atezolizumab + Bevacizumab + Infigratinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST